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The availability of two CAR T-cell therapies on the market has cemented the therapeutic potential of these 
products to treat oncology patients. However, in order for CAR T-cell therapies to be available to a wide number 
of patients, cell therapy developers must carefully design their manufacturing and commercialisation strategy. 
This analysis must take into account multiple factors related to the target market characteristics (EU v USA), the 
product features (e.g. dose size), manufacturing process (e.g. automated v manual platforms) as well as facility 
network (e.g. centralised v bedside manufacture) and supply chain requirements (e.g. fresh v frozen products). 
This presentation aims at assessing the implications of the choices made for each of these critical factors to 
provide a clear framework for decision-making during early stages of the development process of autologous 
CAR T-cell products. The resulting roadmap enables the successful commercialisation of these powerful 
therapeutics. This analysis was carried out using an advanced decisional tool developed at University College 
London. The case study assesses the economic and operational effects of the decisions made at the different 
levels of manufacturing and commercialisation strategy by computing metrics such as cost of goods, fixed 
capital investment, net present value, personnel requirement and facility footprint, while considering potential 
constraints relating to technology capacity, viral vector stock availability, product shelf life, market access and 
reimbursement strategies. 
  
 
